Is Ensysce Biosciences Stock a Good Investment?
Ensysce Biosciences Investment Advice | ENSC |
- Examine Ensysce Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ensysce Biosciences' leadership team and their track record. Good management can help Ensysce Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ensysce Biosciences' business and its evolving consumer preferences.
- Compare Ensysce Biosciences' performance and market position to its competitors. Analyze how Ensysce Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Ensysce Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ensysce Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ensysce Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ensysce Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Ensysce Biosciences Stock
Researching Ensysce Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.71. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ensysce Biosciences recorded earning per share (EPS) of 110.31. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 6th of December 2024.
To determine if Ensysce Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ensysce Biosciences' research are outlined below:
| Ensysce Biosciences generated a negative expected return over the last 90 days | |
| Ensysce Biosciences has high historical volatility and very poor performance | |
| Ensysce Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Ensysce Biosciences currently holds 301.66 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.21 M. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (2.1 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Ensysce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: What analysts say about Ensysce Biosciences Inc. stock - Free Capital Efficiency Planning - printweek.in |
Ensysce Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ensysce Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ensysce Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ensysce Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ensysce Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.39 | -0.22 | 0.17 | 43 | ||
2023-11-09 | 2023-09-30 | -1.06 | -0.87 | 0.19 | 17 | ||
2024-05-13 | 2024-03-31 | -0.9 | -0.55 | 0.35 | 38 | ||
2024-11-07 | 2024-09-30 | -0.29 | 0.07 | 0.36 | 124 | ||
2024-03-15 | 2023-12-31 | -0.87 | -1.37 | -0.5 | 57 | ||
2025-03-19 | 2024-12-31 | -1.95 | -2.9 | -0.95 | 48 | ||
2022-08-11 | 2022-06-30 | -3.4 | -4.8 | -1.4 | 41 | ||
2023-08-11 | 2023-06-30 | -2.73 | -0.98 | 1.75 | 64 |
Know Ensysce Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ensysce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ensysce Biosciences backward and forwards among themselves. Ensysce Biosciences' institutional investor refers to the entity that pools money to purchase Ensysce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Vanguard Group Inc | 2024-12-31 | 0.0 | Anson Funds Management Lp | 2024-12-31 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 0.0 | Hpm Partners Llc | 2024-12-31 | 0.0 | Hrt Financial Llc | 2024-12-31 | 0.0 | Murchinson Ltd. | 2025-03-31 | 140 K | Perceptive Advisors Llc | 2025-03-31 | 86.7 K | Adage Capital Partners Gp Llc | 2025-03-31 | 74.7 K | Sabby Management Llc | 2025-03-31 | 47 K | Fny Investment Advisers, Llc | 2025-03-31 | 3 K |
Ensysce Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.22 M.Market Cap |
|
Ensysce Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.43) | (1.50) | |
| Return On Capital Employed | (1.99) | (1.89) | |
| Return On Assets | (1.43) | (1.50) |
Determining Ensysce Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Ensysce Biosciences is a good buy. For example, gross profit margin measures Ensysce Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ensysce Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Ensysce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ensysce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ensysce Biosciences' management manipulating its earnings.
Evaluate Ensysce Biosciences' management efficiency
Ensysce Biosciences has return on total asset (ROA) of (0.8846) % which means that it has lost $0.8846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2197) %, meaning that it created substantial loss on money invested by shareholders. Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of July 23, 2025, Return On Tangible Assets is expected to decline to -1.5. The current year's Return On Capital Employed is expected to grow to -1.89. The current year's Non Currrent Assets Other is expected to grow to about 265.2 K, whereas Total Assets are forecasted to decline to about 5.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.94 | 2.03 | |
| Tangible Book Value Per Share | 1.94 | 2.03 | |
| Enterprise Value Over EBITDA | (1.64) | (1.72) | |
| Enterprise Value Multiple | (1.64) | (1.72) | |
| Enterprise Value | 12.7 M | 12 M |
Leadership at Ensysce Biosciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.993 |
Basic technical analysis of Ensysce Stock
As of the 23rd of July, Ensysce Biosciences shows the Coefficient Of Variation of 1591.54, downside deviation of 6.38, and Mean Deviation of 5.54. Ensysce Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Ensysce Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ensysce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ensysce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ensysce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ensysce Biosciences' Outstanding Corporate Bonds
Ensysce Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ensysce Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ensysce bonds can be classified according to their maturity, which is the date when Ensysce Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ENTERGY LA LLC Corp BondUS29364WBA53 | View | |
| ENTERGY LA LLC Corp BondUS29364WBB37 | View | |
| US29364WBC10 Corp BondUS29364WBC10 | View | |
| US29364WBE75 Corp BondUS29364WBE75 | View | |
| US29364WBD92 Corp BondUS29364WBD92 | View | |
| ETR 235 15 JUN 32 Corp BondUS29364WBH07 | View | |
| ETR 31 15 JUN 41 Corp BondUS29364WBJ62 | View | |
| ETR 475 15 SEP 52 Corp BondUS29364WBL19 | View |
Understand Ensysce Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ensysce Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.066 | |||
| Market Risk Adjusted Performance | 0.229 | |||
| Mean Deviation | 5.54 | |||
| Semi Deviation | 5.82 | |||
| Downside Deviation | 6.38 | |||
| Coefficient Of Variation | 1591.54 | |||
| Standard Deviation | 13.08 | |||
| Variance | 171.0 | |||
| Information Ratio | 0.0492 | |||
| Jensen Alpha | 0.1877 | |||
| Total Risk Alpha | (1.63) | |||
| Sortino Ratio | 0.1009 | |||
| Treynor Ratio | 0.219 | |||
| Maximum Drawdown | 109.72 | |||
| Value At Risk | (10.94) | |||
| Potential Upside | 9.35 | |||
| Downside Variance | 40.68 | |||
| Semi Variance | 33.85 | |||
| Expected Short fall | (6.52) | |||
| Skewness | 6.1 | |||
| Kurtosis | 44.84 |
| Risk Adjusted Performance | 0.066 | |||
| Market Risk Adjusted Performance | 0.229 | |||
| Mean Deviation | 5.54 | |||
| Semi Deviation | 5.82 | |||
| Downside Deviation | 6.38 | |||
| Coefficient Of Variation | 1591.54 | |||
| Standard Deviation | 13.08 | |||
| Variance | 171.0 | |||
| Information Ratio | 0.0492 | |||
| Jensen Alpha | 0.1877 | |||
| Total Risk Alpha | (1.63) | |||
| Sortino Ratio | 0.1009 | |||
| Treynor Ratio | 0.219 | |||
| Maximum Drawdown | 109.72 | |||
| Value At Risk | (10.94) | |||
| Potential Upside | 9.35 | |||
| Downside Variance | 40.68 | |||
| Semi Variance | 33.85 | |||
| Expected Short fall | (6.52) | |||
| Skewness | 6.1 | |||
| Kurtosis | 44.84 |
Consider Ensysce Biosciences' intraday indicators
Ensysce Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ensysce Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ensysce Biosciences time-series forecasting models is one of many Ensysce Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ensysce Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ensysce Stock media impact
There is far too much social signal, news, headlines, and media speculation about Ensysce Biosciences that are available to investors today. This information is accessible both publicly - through Ensysce Biosciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Ensysce-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Ensysce Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ensysce Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ensysce Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ensysce Biosciences alpha.
Ensysce Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ensysce Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ensysce Biosciences Corporate Management
| MSE MBA | Chief Officer | Profile | |
| Geoffrey Birkett | Chief Officer | Profile | |
| Jeffrey Millard | Chief Officer | Profile | |
| Linda Pestano | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 110.31 | Revenue Per Share | Quarterly Revenue Growth 3.317 | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ensysce Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.